Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2025
Allschwil, Switzerland – May 28, 2025
At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Board of Directors.
The meeting was attended by 166 shareholders, representing a total of 97’748’740 shares, or 43.28% of the total outstanding shares.
Led by the Chairman of the Board, Jean-Paul Clozel the company presented a business update.
Jean-Paul Clozel, MD, Chairman of the Board of Directors, commented:
“On behalf of the Board, I would like to thank the shareholders for their support and loyalty. I strongly believe that with their backing, with our products and pipeline, and with our people working to ramp-up the sales of QUVIVIQ and activate the pipeline, Idorsia can become one of the most successful biotech companies in Europe.”
The shareholders approved the Annual Report 2024, the Consolidated Financial Statements 2024, and the Statutory Financial Statements 2024. Shareholders also endorsed the Compensation Report 2024 and the Sustainability Report 2024 by way of consultative vote.
The shareholders approved the appropriation of available earnings and that the net loss for the year 2024 be carried forward.
The shareholders granted discharge to all members of the Board of Directors and of the Executive Committee for the financial year 2024.
The shareholders approved the amendments to the Articles of Association regarding share capital.
The shareholders re-elected all Board members who stood for re-election for a term of office until the conclusion of the AGM 2026. In addition, the shareholders elected Jean-Paul Clozel as Chairman of the Board, and the members of the Nominating, Governance and Compensation Committee: Srishti Gupta, Mathieu Simon, and Bart Filius. Following the AGM, the Board of Directors of Idorsia comprises a total of 5 members: Jean-Paul Clozel (Chairman), Mathieu Simon, Srishti Gupta, Sandy Mahatme, and Bart Filius.
Shareholders approved the aggregate maximum amount of compensation for the Board of Directors for the term of office until the AGM 2026 and aggregate maximum amount of compensation for the Idorsia Executive Committee (IEC) for the financial year 2026.
BachmannPartner AG, who was represented by Mr Alain Bachmann, was re-elected as Independent Proxy for a term of office until the conclusion of the AGM 2026.
Deloitte AG, Basel, was re-elected as the company’s statutory auditors for the financial year 2025 (for a term of office until the conclusion of the AGM 2026).
Notes to the editor
About Idorsia
Idorsia Ltd is reaching out for more – we have more passion for science, we see more opportunities, and we want to help more patients.
The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients.
Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).
For further information, please contact
Investor & Media Relations
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com
The above information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
Attachment
